| 1 |
33191836 | Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. | 2022 Apr |
1 |
| 2 |
34196110 | Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. | 2022 Apr |
2 |
| 3 |
34957551 | Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study. | 2022 May 15 |
4 |
| 4 |
35300283 | A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. | 2022 |
1 |
| 5 |
35455627 | (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. | 2022 Mar 22 |
1 |
| 6 |
35495161 | Hepatic Models in Precision Medicine: An African Perspective on Pharmacovigilance. | 2022 |
1 |
| 7 |
32047265 | Variations and expression features of CYP2D6 contribute to schizophrenia risk. | 2021 Jun |
1 |
| 8 |
32501544 | Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. | 2021 Feb |
1 |
| 9 |
32713032 | Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. | 2021 Mar |
2 |
| 10 |
33047329 | Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. | 2021 May |
1 |
| 11 |
33320718 | Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics. | 2021 Mar |
2 |
| 12 |
33515076 | Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes. | 2021 Aug |
1 |
| 13 |
33673305 | Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. | 2021 Feb 12 |
5 |
| 14 |
33757925 | [Non-hormonal alternatives for the management of menopausal hot flushes. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines]. | 2021 May |
1 |
| 15 |
33805613 | Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. | 2021 Mar 13 |
1 |
| 16 |
34199712 | Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. | 2021 Jun 4 |
3 |
| 17 |
34284099 | CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. | 2021 Oct |
6 |
| 18 |
34290055 | Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. | 2021 Jul 21 |
1 |
| 19 |
34480554 | Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. | 2021 Dec 1 |
2 |
| 20 |
34570302 | Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. | 2021 Dec |
1 |
| 21 |
34899282 | Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. | 2021 |
1 |
| 22 |
31559573 | Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. | 2020 Jan |
2 |
| 23 |
31758654 | Post-marketing assessment of generic tamoxifen in Brazilian breast cancer patients. | 2020 May |
1 |
| 24 |
31800347 | CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. | 2020 Feb 20 |
4 |
| 25 |
31821071 | CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. | 2020 Feb 20 |
3 |
| 26 |
31877313 | Impact of CYP2D6 Polymorphisms on Tamoxifen Treatment in Patients With Retroperitoneal Fibrosis: A First Step Towards Tailored Therapy? | 2020 Mar |
4 |
| 27 |
31916635 | Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line. | 2020 Jun |
4 |
| 28 |
32080081 | Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant). | 2020 Feb |
2 |
| 29 |
32270286 | Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. | 2020 Jun |
7 |
| 30 |
32273802 | Prevalence of the co-prescription of tamoxifen and CYP2D6 inhibitors in Saudi population: A cross sectional study. | 2020 Apr |
5 |
| 31 |
33161337 | Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. | 2020 Dec |
1 |
| 32 |
33369460 | The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience. | 2020 Dec 1 |
3 |
| 33 |
30357449 | Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis. | 2019 Jan |
2 |
| 34 |
30411242 | CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. | 2019 Feb |
5 |
| 35 |
30542984 | CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. | 2019 Jan |
5 |
| 36 |
30658716 | Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. | 2019 Jan 18 |
1 |
| 37 |
30734152 | Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. | 2019 Sep |
3 |
| 38 |
30786012 | Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. | 2019 Sep |
2 |
| 39 |
30792473 | Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen. | 2019 Feb 21 |
4 |
| 40 |
30843495 | Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population. | 2019 |
6 |
| 41 |
31008668 | Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. | 2019 Jun |
1 |
| 42 |
31178724 | Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites. | 2019 |
6 |
| 43 |
31195002 | Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol. | 2019 Sep 1 |
1 |
| 44 |
31284530 | Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms. | 2019 Jul 5 |
3 |
| 45 |
31344832 | Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer. | 2019 Jul 24 |
2 |
| 46 |
31547390 | CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. | 2019 Sep 12 |
1 |
| 47 |
31852530 | Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. | 2019 Dec 19 |
1 |
| 48 |
34007593 | Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients. | 2019 |
2 |
| 49 |
28540639 | Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. | 2018 Feb |
1 |
| 50 |
28762370 | Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. | 2018 Apr |
1 |